Investigating brain chemistry in youth at risk for psychosis
Ultra-high field GluCEST MRI and MRS in youth at risk for psychosis
This study is looking at how changes in a brain chemical called glutamate might be linked to the development of psychosis in teenagers, and it’s for young people who are at risk for psychosis or already experiencing it, to help find better ways to monitor and treat their condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10802337 on NIH RePORTER |
What this research studies
This research focuses on understanding how changes in brain glutamate levels may contribute to the development of psychosis in adolescents. Using a cutting-edge 7T MRI technique called GluCEST, the study aims to measure glutamate levels in the brains of youth who are at clinical high risk for psychosis, as well as those with established psychosis. By comparing these measurements with typically developing youth, researchers hope to uncover important associations between brain chemistry, structure, and function during critical developmental stages. This could lead to better monitoring and treatment strategies for those at risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include adolescents aged 12-20 who are at clinical high risk for psychosis or have been diagnosed with psychosis.
Not a fit: Patients who are outside the age range of 12-20 or who do not exhibit risk factors for psychosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved early detection and treatment options for adolescents at risk of developing psychosis.
How similar studies have performed: Previous research using similar advanced MRI techniques has shown promising results in understanding brain chemistry related to psychosis, indicating that this approach may yield valuable insights.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Roalf, David R — University of Pennsylvania
- Study coordinator: Roalf, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.